Woodline Partners’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.9M	Hold	500,127	–	–	0.06%	389
2025 Q4	$13.6M	Buy	500,127 +300,836	+151%	+$7.92M	0.05%	387
2025 Q3	$5.16M	Sell	199,291 -1,301,164	-87%	-$30.2M	0.02%	563
2025 Q2	$30.5M	Buy	1,500,455 +312,026	+26%	+$6.07M	0.16%	189
2025 Q1	$21.6M	Sell	1,188,429 -825,586	-41%	-$18.4M	0.14%	216
2024 Q4	$50.9M	Sell	2,014,015 -327,106	-14%	-$8.89M	0.34%	78
2024 Q3	$79.6M	Buy	2,341,121 +1,583,350	+209%	+$60.3M	0.67%	24
2024 Q2	$28M	Buy	757,771 +6,711	+0.9%	+$253K	0.27%	116
2024 Q1	$31.5M	Buy	751,060 +363,408	+94%	+$14.9M	0.29%	105
2023 Q4	$15.4M	Buy	387,652 +280,156	+261%	+$8.24M	0.17%	180
2023 Q3	$2.96M	Buy	107,496 +52,997	+97%	+$1.66M	0.03%	365
2023 Q2	$1.85M	Sell	54,499 -972	-2%	-$32.8K	0.02%	440
2023 Q1	$2M	Buy	+55,471	New	+$2.39M	0.03%	425
2022 Q3	–	Sell	-64,454	Closed	-$1.74M	–	765
2022 Q2	$1.74M	Sell	64,454 -514,738	-89%	-$14.9M	0.03%	452
2022 Q1	$19.7M	Buy	579,192 +319,297	+123%	+$10.2M	0.33%	92
2021 Q4	$10M	Buy	+259,895	New	+$11.3M	0.15%	194